{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:20:11Z","timestamp":1790162411162,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HD094671"],"award-info":[{"award-number":["T32HD094671"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["5T32HG008955-04"],"award-info":[{"award-number":["5T32HG008955-04"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health Career Development Award","award":["K23-AI135090"],"award-info":[{"award-number":["K23-AI135090"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cytomegalovirus (CMV) causes substantial morbidity and mortality after hematopoietic stem cell transplantation (HSCT). There are limited data on risk factors for CMV viremia and the safety of antiviral medications used to treat CMV in children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a single-center retrospective study of children who underwent HSCT between 2000 and 2016. We used log-logistic regression to evaluate associations between clinical characteristics and CMV-free survival at 100 days after HSCT. We compared the incidences of laboratory-defined adverse events (AEs) during treatment with ganciclovir and foscarnet.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 969 children, the median (interquartile range) age was 6.5 (3.1\u201311.5) years, and 80% underwent allogeneic HSCT. Two hundred forty-four (25%) children developed CMV viremia. Older age (odds ratio [OR],\u20050.95; 95% CI, 0.92\u20130.98), male sex (OR,\u20050.71; 95% CI, 0.51\u20130.99), non-Black, non-White race (OR,\u20050.56; 95% CI, 0.36\u20130.87), umbilical cord blood donor source (OR,\u20050.28; 95% CI, 0.08\u20130.97), and CMV seropositivity (R-\/D+: OR,\u20050.17; 95% CI, 0.07\u20130.41; R+\/D-: OR,\u20050.14; 95% CI, 0.09\u20130.21; R+\/D+: OR,\u20050.08; 95% CI, 0.04\u20130.15) were associated with lower odds of 100-day CMV-free survival. Compared with foscarnet, ganciclovir was associated with lower incidences of thrombocytopenia (incidence rate ratio [IRR], 0.38; 95% CI, 0.15\u20130.97), electrolyte AEs (IRR, 0.42; 95% CI, 0.24\u20130.75), endocrine AEs (IRR, 0.52; 95% CI, 0.34\u20130.79), and renal AEs (IRR, 0.36; 95% CI, 0.19\u20130.65).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CMV viremia occurred commonly among children after HSCT, and ganciclovir and foscarnet were associated with distinct toxicity profiles among children with CMV infection. These findings should be considered when developing CMV prevention and treatment strategies for children after HSCT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofab639","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T18:51:31Z","timestamp":1639594291000},"source":"Crossref","is-referenced-by-count":27,"title":["Risk Factors for CMV Viremia and Treatment-Associated Adverse Events Among Pediatric Hematopoietic Stem Cell Transplant Recipients"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1149","authenticated-orcid":false,"given":"Sarah M","family":"Heston","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca R","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA"},{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Vinesett","sequence":"additional","affiliation":[{"name":"Division of Pediatric Transplant and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances M","family":"Saccoccio","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, University of Florida Shands Children\u2019s Hospital, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Pediatric Transplant and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson J","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S","family":"Kelly","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"2022013115462186400_CIT0001","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ajt.16147","article-title":"Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group.","volume":"21","author":"Solano","year":"2021","journal-title":"Am J Transplant"},{"key":"2022013115462186400_CIT0002","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022013115462186400_CIT0003","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bbmt.2011.10.037","article-title":"Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation.","volume":"18","author":"Jang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022013115462186400_CIT0004","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies.","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022013115462186400_CIT0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1083-8791(00)70010-3","article-title":"CMV antigenemia following bone marrow transplantation: risk factors and outcomes.","volume":"6","author":"Osarogiagbon","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022013115462186400_CIT0006","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hemonc.2017.05.001","article-title":"Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation.","volume":"10","author":"Camargo","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2022013115462186400_CIT0007","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"2022013115462186400_CIT0008","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-019-03669-z","article-title":"The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.","volume":"98","author":"Schmidt-Hieber","year":"2019","journal-title":"Ann Hematol"},{"key":"2022013115462186400_CIT0009","doi-asserted-by":"crossref","first-page":"e02284511","DOI":"10.1371\/journal.pone.0228451","article-title":"Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - a single center 11-year analysis.","volume":"15","author":"D\u00fcver","year":"2020","journal-title":"PLoS One"},{"key":"2022013115462186400_CIT0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1399-3062.2007.00242.x","article-title":"Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.","volume":"10","author":"Bordon","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"2022013115462186400_CIT0011","doi-asserted-by":"crossref","first-page":"e13095","DOI":"10.1111\/tid.13095","article-title":"Epidemiology of viral infections among children undergoing hematopoietic stem cell transplant: a prospective single-center study.","volume":"21","author":"Tsoumakas","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2022013115462186400_CIT0012","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199112053252303","article-title":"Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.","volume":"325","author":"Goodrich","year":"1991","journal-title":"N Engl J Med"},{"key":"2022013115462186400_CIT0013","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1182\/blood-2009-02-203307","article-title":"Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.","volume":"113","author":"Zhou","year":"2009","journal-title":"Blood"},{"key":"2022013115462186400_CIT0014","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"key":"2022013115462186400_CIT0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1701302","article-title":"Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.","volume":"22","author":"Moretti","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"2022013115462186400_CIT0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MPH.0000000000000730","article-title":"Cytomegalovirus treatment in pediatric hematopoietic stem cell transplant patients.","volume":"39","author":"Wattles","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"2022013115462186400_CIT0017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/11316080-000000000-00000","article-title":"Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events.","volume":"11","author":"Marshall","year":"2009","journal-title":"Pediatr Drugs"},{"key":"2022013115462186400_CIT0018","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbmt.2011.11.029","article-title":"Important drug interactions in hematopoietic stem cell transplantation: what every physician should know.","volume":"18","author":"Glotzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022013115462186400_CIT0019","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jbi.2010.11.008","article-title":"The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement.","volume":"44","author":"Horvath","year":"2011","journal-title":"J Biomed Inform"},{"key":"2022013115462186400_CIT0020","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-6646-9","volume-title":"Survival Analysis: A Self-Learning Text","author":"Kleinbaum","year":"2012","edition":"3"},{"key":"2022013115462186400_CIT0021","doi-asserted-by":"crossref","first-page":"e14172","DOI":"10.1097\/MD.0000000000014172","article-title":"Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.","volume":"98","author":"Jaing","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"2022013115462186400_CIT0022","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mph.0000174242.80167.9d","article-title":"Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment.","volume":"27","author":"Patel","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"2022013115462186400_CIT0023","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jmii.2015.07.011","article-title":"Science direct risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients.","volume":"50","author":"Wu","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"2022013115462186400_CIT0024","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis.","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"2022013115462186400_CIT0025","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"2022013115462186400_CIT0026","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"2022013115462186400_CIT0027","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/jpids\/piab041","article-title":"Incidence of CMV infection and disease and adverse events associated with antiviral therapy in a retrospective cohort of allogeneic hematopoietic cell transplant recipients at an academic children\u2019s hospital.","volume":"10","author":"Hayes","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2022013115462186400_CIT0028","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation.","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022013115462186400_CIT0029","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pbc.25292","article-title":"Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children.","volume":"62","author":"Hussein","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2022013115462186400_CIT0030","doi-asserted-by":"crossref","first-page":"187.e1","DOI":"10.1016\/j.jtct.2020.11.014","article-title":"Cytomegalovirus-specific immunity recovers more slowly after cord blood transplantation compared with matched sibling donor allogeneic transplantation.","volume":"27","author":"Bejanyan","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2022013115462186400_CIT0031","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.4049\/jimmunol.172.5.3260","article-title":"Persistent and selective deficiency of CD4 + T cell immunity to cytomegalovirus in immunocompetent young children.","volume":"172","author":"Tu","year":"2004","journal-title":"J Immunol"},{"key":"2022013115462186400_CIT0032","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1097\/00007890-199712150-00022","article-title":"Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.","volume":"64","author":"Seu","year":"1997","journal-title":"Transplantation"},{"key":"2022013115462186400_CIT0033","volume-title":"Package insert","author":"Foscarnet.","year":"2014"},{"key":"2022013115462186400_CIT0034","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2020.05.007","article-title":"Biology of blood and marrow transplantation treatment with foscarnet after allogeneic hematopoietic cell transplant (Allo-HCT) is associated with long-term loss of renal function.","volume":"26","author":"Foster","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022013115462186400_CIT0035","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"2022013115462186400_CIT0036","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/516445","article-title":"Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.","volume":"175","author":"Whitley","year":"1997","journal-title":"J Infect Dis"},{"key":"2022013115462186400_CIT0037","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J Pediatr"},{"key":"2022013115462186400_CIT0038","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-13-424","article-title":"Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised state.","volume":"13","author":"Doan","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2022013115462186400_CIT0039","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/j.1875-9114.1987.tb03529.x","article-title":"Ganciclovir hepatotoxicity.","volume":"7","author":"Shea","year":"1987","journal-title":"Pharmacotherapy"},{"key":"2022013115462186400_CIT0040","doi-asserted-by":"crossref","first-page":"1767\u201372","DOI":"10.1001\/archopht.1989.01070020849025","article-title":"Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy.","volume":"107","author":"Heinemann","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"2022013115462186400_CIT0041","first-page":"432","article-title":"Possible ganciclovir-induced hepatotoxicity in patients with AIDS.","volume":"11","author":"Figge","year":"1992","journal-title":"Clin Pharm"},{"key":"2022013115462186400_CIT0042","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1128\/JCM.02515-06","article-title":"Comparison of the Digene Hybrid Capture System Cytomegalovirus (CMV) DNA (version 2.0), Roche CMV UL54 analyte-specific reagent, and QIAGEN RealArt CMV LightCycler PCR reagent tests using AcroMetrix OptiQuant CMV DNA quantification panels and specimens from allogeneic-stem-cell transplant recipients.","volume":"45","author":"Hanson","year":"2007","journal-title":"J Clin Microbiol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab639\/41779579\/ofab639.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/2\/ofab639\/42340889\/ofab639.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/2\/ofab639\/42340889\/ofab639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T15:47:38Z","timestamp":1643644058000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab639\/6463316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab639","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,12,16]]},"article-number":"ofab639"}}